MedTrace Logo

Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)

NCT01140061 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2019-02-08

Study results available
· View outcomes & findings →

Summary

This study will evaluate the incidence of erythema and other local cutaneous irritation after administration of MK-0873 by patch or cream formulation in healthy participants and participants with mild psoriasis. Part I and Part II in healthy participants will be initiated prior to Part III in psoriasis participants. The primary hypotheses of the study are: 1) that MK-0873 is safe and well tolerated in healthy participants and participants with psoriasis and 2) that the maximum plasma concentration of MK-0873 is \<20 nM in healthy participants and participants with psoriasis.

Conditions

Interventions

DRUG

MK-0873 Patch

MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873

DRUG

MK-0873 Cream

MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873

DRUG

Placebo Patch

Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches

DRUG

Placebo Cream

Placebo cream matching MK-0873 0.05%, 0.5%, or 2%

DRUG

Plain patch

Plain patch containing no MK-0873 or placebo

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-01
Primary Completion
2011-03-01
Completion
2011-03-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01140061 on ClinicalTrials.gov